Last month, for the sixth year in a row, Servier, Gold Sponsor of LabCentral, hosted the Golden Ticket Contest and awarded one “Golden Ticket” to support and celebrate a promising early-stage life-science company, developing innovative solutions in areas of high unmet needs – especially in oncology and neurology. This event also showcases the dynamic collaboration between established industry leaders and emerging startups, promising an exciting future for innovation in patient care and medical research.

Following an insightful panel discussion on the industry’s challenges – highlighting how Servier is addressing these challenges and leading the way in precision medicine in the fields of neurology and oncology – the three short-listed startups, Viska Bio, Riboway Therapeutics and Aperture Bio, pitched their business in front of a specially selected Servier jury.

After intense deliberations, the judges selected Viska Bio to receive the Golden Ticket. Viska Bio is a seed-stage biotech company that has developed a novel antibody-enzyme fusion protein that aims to stimulate the immune system in hard-to-treat cancers, starting with glioblastoma. Viska Bio distinguished itself with a compelling and well-supported pitch that skillfully demonstrated the relevance of its business proposal and how it could potentially be complementary to Servier’s ongoing activities.

“Winning the 2025 Servier Golden Ticket will significantly accelerate Viska’s research on V-103, which we hope to advance towards the clinic for treatment of Glioblastoma. Like Servier, Viska is focused on prioritizing the development of cures for brain cancer.” – Eric Fossel, PhD, CEO of Viska Bio

As part of the award, Viska Bio received a $50,000 credit toward space and services available at LabCentral 700, valid for use over a 13‑month period. In addition, Servier will provide access to its team of experts who will offer guidance and feedback to support the company’s early-stage development.